Inogen (NASDAQ:INGN) was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday.
A number of other equities research analysts have also commented on the company. Leerink Swann reiterated an “outperform” rating and issued a $120.00 target price (up previously from $115.00) on shares of Inogen in a research report on Wednesday, November 8th. Zacks Investment Research upgraded Inogen from a “hold” rating to a “buy” rating and set a $131.00 target price on the stock in a research report on Thursday, November 9th. Finally, Needham & Company LLC upped their target price on Inogen from $108.00 to $125.00 and gave the company a “strong-buy” rating in a research report on Wednesday, November 8th. Four analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. Inogen has an average rating of “Buy” and a consensus target price of $103.29.
Shares of Inogen (NASDAQ INGN) traded up $1.35 during mid-day trading on Friday, hitting $116.68. The stock had a trading volume of 200,452 shares, compared to its average volume of 107,803. The stock has a market capitalization of $2,406.98, a price-to-earnings ratio of 94.86, a price-to-earnings-growth ratio of 3.91 and a beta of 1.02. Inogen has a 1-year low of $66.44 and a 1-year high of $130.05.
In related news, EVP Matt Scribner sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $112.35, for a total value of $280,875.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Raymond Huggenberger sold 14,000 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $119.92, for a total value of $1,678,880.00. Following the completion of the transaction, the director now directly owns 7,808 shares of the company’s stock, valued at $936,335.36. The disclosure for this sale can be found here. In the last quarter, insiders sold 113,651 shares of company stock worth $13,299,463. 5.31% of the stock is owned by insiders.
A number of large investors have recently made changes to their positions in the business. BlackRock Inc. lifted its holdings in Inogen by 4.0% in the fourth quarter. BlackRock Inc. now owns 2,306,534 shares of the medical technology company’s stock valued at $274,662,000 after acquiring an additional 87,737 shares during the period. Vanguard Group Inc. lifted its holdings in Inogen by 24.9% in the second quarter. Vanguard Group Inc. now owns 1,515,342 shares of the medical technology company’s stock valued at $144,594,000 after acquiring an additional 301,737 shares during the period. Koch Industries Inc. lifted its holdings in Inogen by 19,485.8% in the second quarter. Koch Industries Inc. now owns 657,102 shares of the medical technology company’s stock valued at $650,000 after acquiring an additional 653,747 shares during the period. Dimensional Fund Advisors LP lifted its holdings in Inogen by 3.4% in the second quarter. Dimensional Fund Advisors LP now owns 519,523 shares of the medical technology company’s stock valued at $49,572,000 after acquiring an additional 17,111 shares during the period. Finally, State Street Corp lifted its holdings in Inogen by 6.8% in the second quarter. State Street Corp now owns 425,662 shares of the medical technology company’s stock valued at $40,619,000 after acquiring an additional 27,250 shares during the period.
COPYRIGHT VIOLATION NOTICE: “Inogen (INGN) Stock Rating Upgraded by BidaskClub” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/10/inogen-ingn-stock-rating-upgraded-by-bidaskclub.html.
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.